Annual Secretarial Compliance Report for the Year ended 31st March, 2025
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma has submitted its Annual Secretarial Compliance Report for FY2024-25, prepared by M/s Dayal & Maur, Company Secretaries, as required under SEBI Listing Regulations. The company was found compliant across all key areas including Secretarial Standards, insider trading rules, board policies, website disclosures, and director eligibility. No penalties, fines, show-cause notices, or regulatory actions were taken by SEBI or stock exchanges during the year. Bharat Serums and Vaccines Limited became a material subsidiary with effect from October 23, 2024. A few related party transactions were not pre-approved by the Audit Committee due to business exigencies but were subsequently ratified.
This is a routine compliance filing with no negative findings, fines, or regulatory actions, which is a positive signal for shareholders as it reflects good corporate governance practices. The only minor note is procedural — some related party transactions were ratified after the fact rather than approved in advance — but this is common and not material.